welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Cardiac and Skeletal Muscle Effects in the Randomized HOPE-Duchenne Trial
source: Neurology
year: 2019
authors: Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marbán L, Ascheim DD, Marbán E, Victor RG
summary/abstract:Objective:
To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD).
Methods:
The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Participants were enrolled at 3 US medical centers between January and August 2016 and followed for 12 months. An independent Data and Safety Monitoring Board provided safety oversight. Cardiac function and structure were assessed by MRI, and analyzed by a blinded core laboratory. Skeletal muscle function was assessed by performance of the upper limb (PUL).
Results:
Twenty-five eligible patients (mean age 17.8 years; 68% wheelchair-dependent) were randomized to CAP-1002 (n = 13) or control (n = 12). Incidence of treatment-emergent adverse events was similar between groups. Compared to baseline, MRI at 12 months revealed significant scar size reduction and improvement in inferior wall systolic thickening in CAP-1002 but not control patients. Mid-distal PUL improved at 12 months in 8 of 9 lower functioning CAP-1002 patients, and no controls (p = 0.007).
Conclusions:
Intracoronary CAP-1002 in DMD appears safe and demonstrates signals of efficacy on both cardiac and upper limb function for up to 12 months. Thus, future clinical research on CAP-1002 treatment of DMD cardiac and skeletal myopathies is warranted.
Classification of Evidence:
This phase I/II study provides Class II evidence that for patients with DMD, intracoronary CAP-1002 is feasible and appears safe and potentially effective.
organization: Cincinnati Children's Hospital Medical Center, USA; University of Florida, USA; Johns Hopkins University, USA; Cedars-Sinai Medical Center, USA; Capricor Therapeutics, USA; Laikon Hospital, GreeceDOI: 10.1212/WNL.0000000000006950
read more
rareRelated
-
Givinostat in Duchenne’s Muscular Dystrophy Long-term Safety and Tolerability StudyThis is an open label, long-term safety,...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
-
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
-
Phase 1/2 Study in Boys With Duchenne Muscular DystrophyThe MoveDMD study is a 3-part, Phase 1/2...
-
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With ...The primary objective of Parts 1 and 2 o...
-
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award WinnersSOUTH PLAINFIELD, N.J., Sept. 6, 2019 ...
-
Capricor Therapeutics Expands Exosome Technology for DMDCapricor Therapeutics is expanding the d...